Apogee Technology, Inc.


	We are developing PyraDerm™, an advanced intradermal drug delivery system along with macromolecular formulations for the enhanced delivery of vaccines, therapeutic agents, and other active ingredients.	Apogee is a biotechnology company developing novel drug delivery systems to address unmet market health needs. For the latest news, check here.
	Learn More	Learn More


01/26/11 Apogee Technology Resumes Trading on the OTC Bulletin Board 10/26/09 Apogee Technology Announces the Publication of an Article on Intradermal Immunization in the Proceedings of the National Academy of Sciences of the U.S.A. (PNAS) 04/30/08 Apogee Reports Completion of In Vivo Proof-of-Concept Studies and Filing of U.S. Patent Application 04/01/08 APOGEE REPORTS FISCAL 2007 RESULTS 01/23/08 Apogee Common Stock Begins Trading on the Over-the-Counter Bulletin Board under ATCS.OB 11/15/07 Apogee Reports 2007 Third Quarter Results 10/01/07 Apogee Enters into a Research Collaboration with St. Jude Children's Research Hospital 08/23/07 Apogee Enters into an Agreement with Vaccine and Infectious Disease Organization (VIDO)

Read Apogee's Press Release regarding publication in PNAS

Children’s Hospital Boston Press Release: release

Presentation Made by Dr. Alexander Andrianov at the First International Conference on Microneedles Held May 24 and May 25, 2010. Presentation

Apogee is proud to announce the publication of an article on intradermal immunization in the Proceedings of the National Academy of Sciences (PNAS). Press Release

The article, scheduled to be published the week of October 26th, 2009, entitled “Poly[di(carboxylatophenoxy)phosphazene] is a potent adjuvant for intradermal immunization" describes important findings on the in vivo and in vitro performance of the Company’s microneedle technology and demonstrates effective intradermal vaccination from an adjuvanted patch delivery system. The paper is coauthored by researchers from Apogee’s R&D team and collaborators from three Universities in Unites States and Canada.

The full article is now freely available to the public at the Online Early Edition of PNAS.